Written by :
Posted on :

March 1, 2021

Kolosis BIO Announces the Appointment of Keegan Begley as President

Salt Lake City, Utah, March 1, 2021

Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Keegan Begley as the company’s President.

“Kolosis is very excited to welcome Keegan as the newest member of our executive team,” said Collin Begley, Chief Executive Officer at Kolosis. “As the company’s new President, and a member of our Board of Directors, Keegan will provide both vital strategic contributions as well as daily leadership for our extensive sales partner network. Keegan is universally regarded as one of the industry’s most talented sales leaders and we are ecstatic to have him in this key position.”

Prior to joining Kolosis, Keegan served as Executive Vice President, Sales at Centurion Therapeutics where he managed an inside and independent sales network supporting MTF Wound Care tissues. Prior to that, Keegan was an award winning sales manager at Orthofix where he represented MTF bone graft tissues.

“I could not be more excited to join the team at Kolosis BIO,” said Keegan Begley. “I believe we are going to build a tremendous success story here at Kolosis. By combining best in class bone graft technologies with a culture built upon relentless responsiveness and execution, we will meet the needs of our distribution partners, their surgeons, and most importantly the patients we serve.”

About Kolosis BIO:

Kolosis BIO is a leading provider of innovative biologic solutions, dedicated to commercializing cutting-edge technologies and delivering market-leading products to the orthopedic industry. As a pure-play biologics company, Kolosis BIO exclusively partners with MTF Biologics to offer superior quality bone graft technologies such as Kore Fiber, a 100% cortical fiber allograft and Prime HD, a pre-hydrated DBM. These allografts are backed by MTF’s proprietary aseptic processing methods that optimally preserve matrix structures and osteoinductive properties.

As the company looks to the future, Kolosis is dedicated to driving innovation in the biologics field, expanding its product offerings and pushing the boundaries of science to enhance patient outcomes. With a focus on relentless execution and bold technologies, Kolosis BIO endeavors to become a leading force in the biologics market. For more information, please visit

About MTF Biologics:

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. They provide unmatched service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.

The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation), expands its reach to patients across the globe. For more information, visit